TurtleTree, a Singaporean biotech firm specializing in cellular agriculture, announced it has achieved the first self-affirmed GRAS (Generally Recognized As Safe) status for its proprietary precision fermentation-produced lactoferrin, LF+.
Achieving GRAS status will allow the company to begin its US commercialization plans, targeting gaps in the lactoferrin market and the plant-based milk industry. Currently limited to infant formulas due to the lack of supply, lactoferrin can fortify adult nutrition products and supplement plant-based milk to close the nutrition gap with dairy milk.
TurtleTree anticipates profitability from LF+ from 2024 onwards, with consumers showing interest in purchasing USD 500 million worth of LF+ over the next five years.
Analyst QuickTake: Lactoferrin is a high-value bioactive milk protein and a powerful component of cow's milk that helps regulate iron absorption into the body from the intestine. Benefits include improving physical performance, aiding endurance, fatigue resistance, muscle strength, and energetic efficiency in athletic performance.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.